CH stock · Healthcare sector · Biotechnology
Company Logo

CRISPR Therapeutics AG

CRSPNASDAQ

63.16

USD
-1.74
(-2.68%)
Market Closed
16.80P/E
-8Forward P/E
0.84P/E to S&P500
4.927BMarket CAP
- -Div Yield

CRISPR Therapeutics AG

NASDAQ:CRSP

RECENT
PRICE

63.16

P/E
RATIO

16.80

(PEG:0.09)

P/E RATIO
RELATIVE
TO S&P

0.84

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.96 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 09/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

- -

- -

- -

- -

- -

- -

- -

- -

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

(0.23)

(0.16)

- -

0.01

(1.28)

2.88

- -

0.42

(1.89)

(4.76)

- -

1.02

(1.71)

(1.94)

- -

0.07

(3.44)

(2.06)

- -

5.32

1.23

0.92

- -

0.01

(5.29)

(3.89)

- -

13.87

5.73

6.93

- -

0.18

(8.23)

(6.71)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

(0.24)

0.06

(1.44)

0.25

19.00

0.20

4.69

0.06

8.18

0.12

17.27

0.28

25.23

1.24

36.38

0.93

30.07

CAPEX per share

Book Value per share

- -

- -

- -

- -

- -

- -

- -

- -

29

20

12

40

48

54

66

66

77

Comm.Shares outs.(m)

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

(9.9)

(0.4)

- -

(10.9)

(0.5)

- -

(13.6)

(0.5)

- -

36.6

1.5

- -

(15.0)

(0.4)

- -

21.6

0.7

- -

16.8

0.8

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/6/22 | Q2)

Total liabilities
$373 m.

Total assets
$2,463 m.

Long-term debt
$234 m.

Cash and equiv.
$497 m.

Goodwill - -

Retained earnings $(561) m.

Common stock 78 m. shares

Market Capitalisation
$4,927 m. (as of 25/9/22)

- -

- -

- -

- -

- -

- -

- -

(Infinity)%

0

(10,416.6)%

5

(1,319.3)%

41

(157.7)%

3

(5,087.8)%

290

16.1%

1

(49,295.5)%

915

40.8%

14

(57,903.6)%

Revenue (m)

Operating margin

- -

- -

- -

- -

- -

- -

0

(7)

0

(26)

1

(23)

3

(68)

4

(165)

5

67

9

(349)

18

378

25

(633)

Depreciation (m)

Net profit (m)

- -

- -

- -

- -

- -

- -

0.9%

(Infinity)%

(0.0)%

(10,456.7)%

(2.1)%

(449.3)%

(2.6)%

(166.7)%

(0.3)%

(5,281.1)%

0.7%

23.1%

(0.2)%

(48,520.9)%

0.5%

41.3%

(0.9)%

(58,706.6)%

Income tax rate

Net profit margin

- -

- -

- -

- -

- -

- -

- -

- -

- -

(1)

- -

(7)

147

38

(29)

298

- -

233

234

- -

188

439

- -

392

930

- -

939

1,622

50

1,664

2,298

213

2,399

1,987

234

2,091

Working capital (m)

Long-term debt (m)

Equity (m)

- -

- -

- -

- -

- -

- -

- -

- -

- -

892.4%

(495.9)%

95.5%

(17.2)%

(16.1)%

88.8%

(4.6)%

(4.3)%

(10.0)%

(26.6)%

(24.5)%

(36.4)%

(35.8)%

(33.6)%

(42.1)%

6.6%

6.3%

7.1%

(20.1)%

(19.0)%

(21.0)%

14.3%

13.8%

15.7%

(27.0)%

(25.4)%

(30.3)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

944

1,169

923

Receivables

0

0

0

Inventory

- -

- -

- -

Other

44

26

38

Current assets

988

1,717

2,418

Acc. Payable

6

9

15

Debt due

8

11

12

Other

43

74

93

Current liab.

57

94

120

- -

- -

- -

- -

- -

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

(830.2)%

100.0%

- -

100.0%

(46.6)%

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

CRISPR Therapeutics AG (CH) started trading on October 3, 2016 (cik: 0001674416), operates in the Healthcare sector (Biotechnology industry), has 473 full-time employees, and is led by Dr. Samarth Kulkarni. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

34033.16%

- -

Cash flow

-253.76%

- -

Earnings

-207.31%

- -

Dividends

- -

- -

Book value

92.42%

- -

Insider trading

Type

Shares

Date

Kulkarni Samarth

Exempt

25,000

08/29/22

Kulkarni Samarth

Sale

163

08/29/22

Kulkarni Samarth

Sale

20,764

08/29/22

Kulkarni Samarth

Sale

4,073

08/29/22

Kulkarni Samarth

Exempt

25,000

08/29/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

0

0

0

0

1

2021

1

901

1

13

915

2022

0

0

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(1.06)

(1.21)

(1.40)

(1.62)

-5.29

2021

(1.72)

11.51

(1.93)

(2.14)

5.73

2022

(2.32)

(2.40)

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -